KRYS Krystal Biotech, Inc.
FY2025 10-K
Krystal Biotech, Inc. (KRYS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: commercializing gene therapies targeting rare monogenic diseases, led by approved topical VYJUVEK for dystrophic epidermolysis bullosa (DEB)
- • New emphasis on diverse clinical pipeline including KB407 (cystic fibrosis), KB408 (AAT deficiency), ophthalmic KB803 & KB801, dermatology KB111, oncology KB707, and aesthetics via Jeune Aesthetics
Management Discussion & Analysis
- • No revenue or profitability data disclosed in the provided MD&A excerpt
- • No segment performance or cash flow details included
Risk Factors
- • Regulatory risk from Biologics Price Competition and Innovation Act (BPCIA) allowing biosimilar competition after 12 years exclusivity on VYJUVEK
- • Geopolitical risk from uncertain regulatory approval of VYJUVEK outside U.S., EU, Japan limiting international revenue
Financial SummaryXBRL
Revenue
$389M
Net Income
$205M
Operating Margin
41.5%
Net Margin
52.6%
ROE
16.8%
Total Assets
$1.3B
EPS (Diluted)
$6.84
Operating Cash Flow
$201M
Source: XBRL data from Krystal Biotech, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Krystal Biotech, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.